Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study

The Lancet

Volumn 387, Issue 10019, 2016, Pages 679-690

  Armstrong, Matthew James ^a,b   Gaunt, Piers ^c   Aithal, Guruprasad P ^d   Barton, Darren ^a,c   Hull, Diana ^a,c   Parker, Richard ^a,b   Hazlehurst, Jonathan M ^e   Guo, Kathy ^a,c   Abouda, George ^f   Aldersley, Mark A ^g   Stocken, Deborah ^h   Gough, Stephen C ^e   Tomlinson, Jeremy W ^e   Brown, Rachel M ^b   Hübscher, Stefan G ^b,c   Newsome, Philip N ^a,b  

^a University of Birmingham   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f HULL ROYAL INFIRMARY   (United Kingdom)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; PLACEBO; SULFONYLUREA; INCRETIN;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BLOATING; BODY MASS; CHEST INFECTION; CHILL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EYE DISEASE; FATIGUE; FEMALE; FLATULENCE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HEADACHE; HEART DISEASE; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; KIDNEY DISEASE; LIVER BIOPSY; LOSS OF APPETITE; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCLE CRAMP; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUTRITIONAL DISORDER; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE DISEASE; URINARY TRACT DISEASE; URINARY TRACT INFECTION; VOMITING; ADOLESCENT; AGED; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCRETINS; INJECTIONS, SUBCUTANEOUS; LIRAGLUTIDE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957840942     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00803-X     Document Type: Article

References (31)

1. MR Charlton, JM Burns, RA Pedersen et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States Gastroenterology 141 2011 1249 1253
2. MJ Armstrong, LA Adams, A Canbay et al. Extra-hepatic complications of nonalcoholic fatty liver disease Hepatology 59 2014 1174 1197
3. ZM Younossi, M Stepanova, N Rafiq et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality Hepatology 53 2011 1874 1882
4. M Ekstedt, H Hagstrom, P Nasr et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up Hepatology 61 2015 1547 1554
5. N Chalasani, Z Younossi, JE Lavine et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 142 2012 1592 1609
6. G Musso, R Gambino, M Cassader et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease Hepatology 52 2010 79 104
7. AJ Sanyal, N Chalasani, KV Kowdley et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
8. BA Neuschwander-Tetri, R Loomba, AJ Sanyal et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 385 2015 956 965
9. V Ratziu Pharmacological agents for NASH Nat Rev Gastroenterol Hepatol 10 2013 676 685
10. LL Baggio, DJ Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157
11. LB Knudsen, PF Nielsen, PO Huusfeldt et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J Med Chem 43 2000 1664 1669
12. A Astrup, S Rössner, L Van Gaal et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 2009 1606 1616
13. RR Henry, JB Buse, G Sesti et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program Endocr Pract 17 2011 906 913
14. J Lee, S-W Hong, SW Chae et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice PLoS One 7 2012 e31394
15. X Ding, NK Saxena, S Lin et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Hepatology 43 2006 173 181
16. JE Mells, PP Fu, S Sharma et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet Am J Physiol Gastrointest Liver Physiol 302 2012 G225 G235
17. JL Trevaskis, PS Griffin, C Wittmer et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice Am J Physiol Gastrointest Liver Physiol 302 2012 G762 G772
18. S Ben-Shlomo, I Zvibel, M Shnell et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase J Hepatol 54 2011 1214 1223
19. NA Gupta, J Mells, RM Dunham et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway Hepatology 51 2010 1584 1592
20. M Ellrichmann, K Vollmer, H Schrader et al. Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis Am J Gastroenterol 104 2009 3112 3114
21. ME Tushuizen, MC Bunck, PJ Pouwels et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis Liver Int 26 2006 1015 1017
22. PR Kenny, DE Brady, DM Torres et al. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series Am J Gastroenterol 105 2010 2707 2709
23. JB Buse, DC Klonoff, LL Nielsen et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Clin Ther 29 2007 139 153
24. MJ Armstrong, DD Houlihan, IA Rowe et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program Aliment Pharmacol Ther 37 2013 234 242
25. MJ Armstrong, D Barton, P Gaunt et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial BMJ Open 3 2013 e003995
26. AJ Sanyal, EM Brunt, DE Kleiner et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis Hepatology 54 2011 344 353
27. DE Kleiner, EM Brunt, M Van Natta et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
28. R Belfort, SA Harrison, K Brown et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 2006 2297 2307
29. P Angulo, DE Kleiner, S Dam-Larsen et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease Gastroenterology 149 2015 389 397
30. G Svegliati-Baroni, S Saccomanno, C Rychlicki et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int 31 2011 1285 1297
31. S Sharma, JE Mells, PP Fu et al. GLP-1 Analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy PLoS One 6 2011 e25269